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Abstract
Background: Dengue is a growing problem both in its geographical spread and in its intensity, and yet current global
distribution remains highly uncertain. Challenges in diagnosis and diagnostic methods as well as highly variable national
health systems mean no single data source can reliably estimate the distribution of this disease. As such, there is a lack of
agreement on national dengue status among international health organisations. Here we bring together all available
information on dengue occurrence using a novel approach to produce an evidence consensus map of the disease range
that highlights nations with an uncertain dengue status.
Methods/Principal Findings: A baseline methodology was used to assess a range of evidence for each country. In regions
where dengue status was uncertain, additional evidence types were included to either clarify dengue status or confirm that
it is unknown at this time. An algorithm was developed that assesses evidence quality and consistency, giving each country
an evidence consensus score. Using this approach, we were able to generate a contemporary global map of national-level
dengue status that assigns a relative measure of certainty and identifies gaps in the available evidence.
Conclusion: The map produced here provides a list of 128 countries for which there is good evidence of dengue
occurrence, including 36 countries that have previously been classified as dengue-free by the World Health Organization
and/or the US Centers for Disease Control. It also identifies disease surveillance needs, which we list in full. The disease
extents and limits determined here using evidence consensus, marks the beginning of a five-year study to advance the
mapping of dengue virus transmission and disease risk. Completion of this first step has allowed us to produce a preliminary
estimate of population at risk with an upper bound of 3.97 billion people. This figure will be refined in future work.
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Introduction
Despite increased interest in dengue in recent years, the global
distribution of dengue remains highly uncertain. Estimates for the
population at risk range from 30% [1] to 54.7% [2] of the world’s
population (2.05–3.74 billion) while the Centers for Disease
Control (CDC) and the World Health Organization (WHO)
currently disagree on dengue presence in 34 countries across five
continents (Table S1). Clinical features of dengue virus infection
include fever, rash and joint pain [3], which ensure the disease’s
misdiagnosis and mis-reporting among many other febrile
illnesses. The diagnostic methods available also have limitations
and a full complement of tests is not feasible in many healthcare
settings. There is consensus, however, that dengue is a growing
problem both geographically and in its intensity [4,5,6].
There is an urgent need to compile more extensive occurrence
records of dengue virus transmission and assess them for
contemporariness and accuracy. Evidence on dengue transmission
comes in a wide variety of forms, with varying levels of spatial
coverage and reliability. A global audit of dengue distribution
therefore requires a transparent methodology to compile these
disparate data types and synthesise an output map summarising
the current consensus for each country. Such a methodology for
compiling and assessing evidence must be robust, repeatable, able
to evaluate a large variety of evidence types and incorporate expert
opinion. An ideal output metric is a summary statistic (hereafter
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7referred to as evidence consensus) that quantifies certainty on
dengue virus transmission presence or absence given the accuracy
and contemporariness of the evidence available. An evidence-
based map of the current distribution of dengue virus transmission
will have direct implications for design and implementation of
dengue surveillance and, by showing gaps in contemporary
knowledge, provide an advocacy platform for improved data.
Existing approaches to mapping the global limits of vector-
borne diseases have used estimates of biological suitability of local
environments, which have proved informative in the cases of some
pathogens, such as Plasmodium falciparum [7,8] and P. vivax [9].
Several approaches have been used to map biological suitability
for dengue using non-dengue-specific variables such as tempera-
ture, rainfall and satellite-derived environmental variables
[1,10,11]. Although successive attempts have each increased
predictive capacity and resolution, this approach produces
variable results in Africa due to a scarcity of confirmed occurrence
points across extensive geographic areas. An alternative approach
has been to map evidence of dengue occurrence making no
assumptions about biological suitability, as in Van Kleef et al., who
reviewed published literature to contrast historic, current and
future limits of dengue [5]. To date dengue mapping has focussed
on future scenarios, yet understanding of the current distribution
of dengue virus transmission is far from complete and needs to be
better evaluated before we can make predictions about forthcom-
ing patterns and trends. In this study we combine evidence from
large occurrence-point style databases used in biological suitability
mapping approaches with a wider systematic review of various
sources of evidence to create a more comprehensive dengue
database. Using this database we then use the novel method of
defining evidence consensus to evaluate the current level of
certainty on dengue virus transmission presence or absence at
national (and some sub-national) levels using a weighted evidence
scoring system. Finally, we present these results as a series of global
maps that explicitly identify surveillance gaps.
This study is the initial part of a five year project to collect,
analyse and publicise global dengue virus transmission data. While
the map presented here is the most extensive display of current
dengue evidence available, we hope that continual data acquisition
will result in more evidence from uncertain areas, increasing the
resolution at which we can map evidence consensus in future
advances.
Methods
Collection of dengue virus transmission evidence
Evidence for indigenous dengue virus transmission was obtained
from four evidence categories: health organisations, peer-reviewed
evidence, case data and supplementary evidence (Figure 1). The
first three categories were used for all countries. For countries
where some of these categories were not available and/or did not
provide good consensus, the fourth category of supplementary
evidence was used. Evidence was initially collected at a country
level (Admin0), but resolution was improved to a state/province
level (Admin1) or district level (Admin2) at the fringes of the
distribution of detectable virus transmission when sufficient data
were available.
Country dengue status as defined by health organisations was
determined by consulting the WHO [12] and CDC [13] dengue
distribution maps as well as the Global Infectious Diseases and
Epidemiology Online Network (GIDEON) database [14]. GID-
EON provides a collection of literature and case reports for a
range of tropical and infectious diseases in 224 countries. Dengue
status by country was recorded as present or absent.
The peer-reviewed evidence category contained evidence of
dengue occurrence as determined by peer-reviewed sources where
details of diagnostic techniques were given. Peer-reviewed journal
(Google Scholar, PubMed, ISI Web of Science) and disease
surveillance network (ProMED archives, Eurosurveillance ar-
chives) searches were conducted with search terms ‘‘country’’ or
‘‘Admin1/2’’ and ‘‘dengue’’. Sources were included for the period
1960–2012 and only if cases were confirmed as resulting from
indigenous (i.e. not imported) transmission. The specialist regional
journal collections African Journals Online (http://www.ajol.
info/) and China National Knowledge Infrastructure (http://en.
cnki.com.cn/) were also searched. Extra publications were found
by searching using the location term in Genbank nucleotide
records for dengue viruses isolated from human hosts. The search
of peer-reviewed sources of evidence resulted in a total of 285
articles being selected for 123 countries where positive dengue
occurrence records were identified. This included evidence from
returning travellers who were diagnosed upon return to their often
non-endemic home countries as opposed to the transmission
setting. For these cases, evidence was attributed to the place to
which they had travelled. The added value of returning traveller
reports is that the travellers are often more immunologically naı ¨ve
to dengue infections, and also that diagnosis is often pursued more
rigorously. Therefore, the sensitivity of detecting an infection is
increased. The results of our search were then cross-referenced
against a dengue occurrence-point database compiled internally,
in a separate exercise. Unlike our country-specific searches, this
database of 2836 articles results from searches simply for
‘‘dengue’’, which were then geo-referenced using the article text.
Full details are available in Protocol S1 and the geographic
location of the occurrence points are displayed in Figures S1, S2,
S3, S4, S5, S6. This cross-referencing resulted in the inclusion of
an additional 16 articles in the current analysis and also provided
increased justification for our choice of countries to evaluate at
Admin1 level.
The case data category contained evidence of dengue outbreaks
(minimum 50 infections) where evidence contained less diagnostic
Author Summary
Previous attempts to map the current global distribution
of dengue virus transmission have produced variable
results, particularly in Africa, reflecting the lack of accuracy
in both diagnostic and locational information of reported
dengue cases. In this study, instead of excluding these less
informed points we included them with appropriate
uncertainty alongside other diverse evidence forms. After
assembling a comprehensive database of different evi-
dence types, a weighted scoring system calculated
‘‘evidence consensus’’ for each country a continuous
measure of the certainty of dengue presence or absence
when considering the full aggregate of evidence. The
resulting map and analysis helped highlight important
evidence gaps that underlie uncertainties in the current
distribution of dengue. We also show the importance of
local knowledge through incorporating questionnaire-
based responses that can help add clarity in uncertain
regions. This analysis showed that presence/absence maps
do not sufficiently highlight the uncertainties in the
evidence base used to construct them. Mapping by
evidence consensus not only encourages greater data
inclusion, but it also better illustrates the current global
distribution of dengue. Consensus mapping is thus ideal
for a range of neglected tropical diseases where the
evidence base is incomplete or less diagnostically reliable.
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transmission occurring. Case data from the most recent outbreak
were obtained from the Program for Monitoring Emerging
Diseases (ProMED) archive search, WHO DengueNet data query
[15] and from GIDEON which holds a detailed record of
government-reported case numbers. This resulted in 100 countries
with useful dengue case data.
In many resource-poor countries, both surveillance and
researcher-generated reports are rare. Therefore, in countries
where other evidence categories were sparse, we looked for
supplemental evidence that suggested possible dengue virus
presence. Supplemental evidence types included: presence of an
established mosquito vector population of public health signifi-
cance (Aedes aegypti, Ae. albopictus or Ae. polynesiensis) as documented
by peer-reviewed literature, confirmed presence of multiple other
rarely diagnosed arboviral diseases as documented by peer-
reviewed literature, news reports of dengue epidemics found using
GoogleNews archives (http://news.google.co.uk/archivesearch)
and travel advisories from the National Travel Health Network
and Centre (http://www.nathnac.org/ds/map_world.aspx) issued
at a country-level. We included evidence of multiple other rarely
diagnosed arboviral diseases, as these are informative about the
ability of a country to detect any possible dengue infection. If other
arboviral diseases are poorly reported, but documented by peer-
reviewed literature as present, then it is possible that dengue is also
underreported. In addition to this, we cross-referenced our dataset
with the HealthMap database (www.healthmap.org/dengue/).
This website-based application automatically geo-positions cases
from websites with news reports and outbreak alerts related to
dengue and contains data from a wide variety of sources dating
back to 2007 [16,17]. This extensive database contributed
important evidence especially at smaller spatial scales and in
areas where translated articles are not so easily obtained.
Supplementary evidence was used in evaluating dengue consensus
in 45 countries.
While the categories are clearly defined here and in Figure 1,
some overlap of evidence sources did occur, depending on the
information content of each source. This meant evidence sources
such as ProMED reports could be included twice, in both the peer-
reviewed evidence and case data categories, if they contained
information about diagnostic tests used for confirmation as well as
overall outbreak case numbers. In this section we outline the main
sources used for each category, but it should be noted that if
evidence from a particular source fitted the criteria for a different
Figure 1. Schematic overview of the methods. Blue diamonds describe input data; orange boxes denote experimental procedures; green ovals
indicate output data; dashed lines represent intermediate outputs and solid lines final outputs; dotted white ovals denote the number of countries
for which data was available and added to the final output. Dotted rectangles identify the different evidence categories and their main data sources.
S1=Protocol S1.
doi:10.1371/journal.pntd.0001760.g001
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category.
Quantifying evidence with a weighted scoring system
In order to quantify evidence consensus, a weighted scoring
system was developed that attributed positive values to evidence of
presence and negative values to evidence of a lack of presence.
The aim here was to use an optimal subset of evidence to
accurately assess dengue status within a given area. By scoring the
evidence categories mentioned above individually and then
combining their respective scores, we were able to calculate
‘‘evidence consensus,’’ a measure of how strongly the combined
evidence collection supports a dengue-present or dengue-absent
status (Figure 2). We defined a country as having ‘‘complete
consensus’’ on dengue presence when the evidence base was
comprised of contemporary forms of most or all of the following
evidence types: 1) unanimous health organisations agreement, 2) a
seroprevalence survey, 3) Polymerase Chain Reaction (PCR)
typing of dengue virus or dengue viral RNA, 4) a foreign visitor to
the area with a confirmed dengue infection upon returning to their
home country, and 5) records of an epidemic of greater than 50
infections. Such a country has a consensus score of between 80%
and 100%. A country with a complete consensus on dengue virus
absence is characterised by all health organisations agreeing on
dengue absence and high healthcare expenditure (as an approx-
imate proxy for surveillance capability), therefore accounting for
both the observed absence of dengue and the minimised possibility
of any undetected dengue infections. Such a country scores
between 280% and 2100% on our scale. A country with no
consensus on dengue virus status is characterised by conflicting
evidence from different categories and scores close to 0%. Each
evidence category was scored independently and category weights
applied to reflect the level of detail each category provides: health
organisation status (maximum score 6), peer-reviewed evidence
(maximum 9), case data (maximum 9) and supplementary
evidence (maximum 6). To support the choice of assigned category
weights we performed a sensitivity analysis in which two
alternative evidence weighting scenarios were applied to the same
sources of data: 1) neutral (all categories hold the same weight) and
2) reversed (health organisation status and supplementary evidence
hold weight 9, peer-reviewed evidence and case data hold weight
6). We then checked for any major deviations in overall country
score resulting from such alternative scenarios.
Health organisation evidence. The data from the three
health organisations (WHO, CDC and GIDEON) comprised
discrete presence or absence answers. A consensus (+++ or 222)
scored 6 or 26 respectively, while a lack of consensus (++2 or
22+) scored 3 or 23 respectively (Figure 2A). This gave a
maximum score for this category of 66.
Peer-reviewed evidence and returning traveller
reports. These forms of evidence were each scored indepen-
dently for contemporariness and accuracy. The date of occurrence
was used for scoring as follows: between 2012–2005=3, 2004–
1997=2 and pre-1997=1 (Figure 2B). This corresponded to a
conservative estimate of the inter-epidemic period for dengue of
three to five years [18]. This score was then added to a score for
accuracy, whereby high accuracy, and a score of 3, was
characterised by PCR methods, a Plaque Reduction Neutraliza-
tion Test (PRNT), or a detailed case description of a complication
of the disease. Complications of the disease were either dengue
haemorrhagic fever (DHF) grades 1 and 2 or dengue shock
syndrome (DSS) grades 3 and 4 under the old classification scheme
[19] or severe dengue under the new classification scheme [3].
Medium accuracy methods including IgM- and IgG- based ELISA
and Hemagglutination Inhibition (HI) assay approaches scored 2
because their calibration is sensitive to background immune
responses [20], antibody response is variable over the course of an
infection [21] and the test can cross-react with other non-dengue
arboviruses [20]. A low accuracy score of 1 was used for articles
that only reported case numbers with a non-dengue-specific case
definition or a low participant number. Each included article was
scored separately and then an average score was taken from all
articles. This presented the possibility of devaluing the score of the
most accurate and contemporary piece of evidence, so an extra
score was added to reflect increased certainty provided by multiple
forms of evidence. Evidence types 2) through 5) described above
contributed to this extra score as such: if two types of evidence
were present a score of 1 was added, three types=2, four
types=3. This resulted in a maximum available score of 9 for
peer-reviewed evidence.
Case data. This category was scored by contemporariness in
eight-year intervals. The most frequent year in which an outbreak
(over 50 cases or over 15 cases if the population is below 100,000)
occurred was again scored in average inter-epidemic period
intervals: 0–7 years since the last outbreak scored 9, 7–14
years=6, 14–21=3, 21–28=23, 28–35=26, 35+=29
(Figure 2C). Where case data were unavailable, the distinction
between true absences and inadequate surveillance was made
using total annual healthcare expenditure (HE) per capita at
average U.S. Dollar exchange rates (2011 WHO health statistics)
[22]. Higher HE has been linked to better overall public health
infrastructure, which includes high-quality diagnostic resources,
greater healthcare coverage and higher levels of expertise, all of
which may result in a more thorough characterisation of dengue
status at the country-level [23,24,25]. Therefore, the lower the
HE, the less certain we can be that an absence of case data
accurately reflects an absence of dengue transmission. Class
intervals for HE were chosen to reflect regional differences both
within and between continents. Where information on HE was
unavailable (Somalia, North Korea and Zimbabwe), low HE status
was assigned. All overseas territories were assumed to have the
same HE as their parent nations. The following criteria were used
to derive the case scores in the absence of dengue case data:
HE,$100 and reports of sporadic unconfirmed cases gave a score
of 6, HE,$100=low HE=3, $100#HE,$500=medium
HE=23, HE$$500=high HE=29 (Figure 2C). The maximum
score for the case data category was 69.
Supplementary evidence. This formed part of the evidence
base if there was some suggestion of dengue presence, but the
above three categories were insufficient to provide certainty on
dengue status. If only two evidence types were available (see
above), a score of 2 was given, three types=4, four types=6
(Figure 2D). Supplementary evidence carried a maximum score of
6.
Where a national score showed some uncertainty and an
additional factor existed that was not captured by the default
scoring system, an adjustment of up to 63 was applied. For
example, if multiple evidence categories suggested dengue
presence in a country with high HE, but there was no case data,
then the case data score was adjusted so as not to hold a
disproportionate weight in deciding overall dengue status. This is
termed the ‘‘ad hoc adjustment’’ (Figure 2E).
To derive an overall country evidence consensus score, the
scores for all evidence categories were summed, and then divided
by the maximum possible score and multiplied by 100. Evidence
consensus was then mapped according to nine equal interval
categories from 100% to 2100% that differentiated evidence
consensus worldwide, with evidence consensus being defined as
Global Dengue Distribution by Evidence Consensus
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(634% to 656%), poor (612% to 33%) or indeterminate (211%
to 11%). An odd number of intervals was chosen so as to highlight
places where consensus is very low (indeterminate) and where
improved surveillance is particularly needed. As such, the resulting
classification of consensus scores should not be strictly interpreted,
but rather taken as a general indication of the quality of dengue
evidence in a given location. A full breakdown of the exact
evidence included, individual scores and overall consensus
percentages are given for each country in Table S1 and Figure S7.
Refining the evidence base and map with questionnaires
targeted to consensus poor countries
In countries where evidence consensus was at best moderate, we
attempted to increase consensus through targeted questionnaires.
The questionnaire asked about endogenous surveillance and data
collection. If available, diagnostic method(s) and summary results
were requested. Any returned data or reports were then entered
into their relevant evidence categories and scored in combination
with existing evidence. Questionnaires were distributed to
healthcare officials in the country of interest as well as selected
offices of the Institut Pasteur. Questionnaire responses and expert
comments are part of an on-going process that will lead to future
modifications of this map.
Identification of countries that publically distribute
dengue case data
To map public awareness of dengue worldwide, we searched the
ministry of health websites of each of the 128 countries identified
as dengue-present (evidence consensus positive but not indetermi-
nate). A country was indicated as publicly displaying dengue data
if national dengue case numbers were displayed annually or during
epidemic years at a minimum.
Population at risk calculations
To calculate the maximum possible population at risk for
dengue virus transmission we obtained total population counts
from the Global Rural Urban Mapping Project (GRUMP) for the
Figure 2. Overview of the evidence scoring system. Cream boxes represent mandatory categories while red boxes represent optional
categories that are only used where required (see Methods). Dashed lines surround individual parameters that are assessed and totalled in the
scoring system. Green boxes describe the level of evidence, with a given score in the blue oval. * Each individual piece of literary evidence is scored
for contemporariness and accuracy before taking an average of the whole set then adding the combination score. Evidence consensus is calculated
as the proportion of the maximum possible score from the dashed lined characteristics that are used. D Maximum possible score depends on which
categories are included and can vary from 15 (Case data and Health organisation status, but no peer-reviewed evidence available) to 30 (all evidence
categories included). Yrs=years. HE=total healthcare expenditure per capita at average U.S. $ exchange rates.
doi:10.1371/journal.pntd.0001760.g002
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version provides gridded population count estimates at a 161k m
spatial resolution for the year 2000 [26,27]. Population counts for
the year 2000 were projected to 2010 by applying country-specific
urban and rural national growth rates [28] using methods
described previously [29]. As 2010 forms a landmark year for
many national censuses, we were able to adjust these expanded
population counts using the United Nations 2010 population
estimates [30].
Results
Global distribution of dengue virus transmission based
on evidence consensus
The global distribution of dengue virus transmission as defined
by evidence consensus is shown in Figures 3–7. The mapped
colour scale ranges from complete consensus on dengue presence
(dark red) to indeterminate consensus on dengue status (yellow)
then through to complete consensus on dengue absence (dark
green). A full list of the evidence used for each area and their
scoring is available in Table S1 and Figure S7. In total we
identified 128 countries as dengue-present (i.e. positive values
outside the indeterminate range), compared to 100 from the
WHO, 104 from the CDC and 118 from GIDEON. Compared to
the lists produced by the WHO and CDC, we identified 41
additional countries where evidence consensus for presence was
outside the indeterminate range yet dengue-absent status was
assigned by at least one of these health organisations.
Even after performing the sensitivity analysis described earlier,
the number of countries defined by our methodology as dengue-
present but defined by WHO/CDC as absent never dropped
below 36 (Table 1). We therefore suggest that this list of 36
countries be subject to a review regarding their current health
organisation dengue-absent classification. Of these countries, 31
had at least moderate consensus on dengue presence in our final
analysis.
The majority of these newly identified dengue-present countries
were in Africa and the evidence type that allowed greatest
identification was returning traveller reports. These sporadic
reports established preliminary evidence, which we improved with
supplementary evidence and questionnaire retrieval to clarify
dengue status if possible (Table 2). Outside of Africa, the
remaining newly identified countries were almost exclusively
islands in the Indian and Pacific Oceans and in the Caribbean.
The reason for a lack of dengue presence identification by health
organisations here is likely the longer interval between epidemics
in small isolated nations, resulting in sparse data which different
health organisations have interpreted inconsistently. Inclusion of
less official surveillance evidence, such as ProMED reports, that
detected background case loads alongside officially reported
outbreaks allowed our distinction of these areas as in fact
dengue-present.
A total of 3.97 billion people live in these 128 countries outside
the indeterminate consensus class. Of these, 824 million live in
urban and 763 million in peri-urban areas. These numbers
therefore constitute plausible preliminary estimates for the
maximum possible population at any risk of dengue transmission.
We expect more comprehensive population at risk calculations to
refine this figure and quantify levels of risk in our future work,
allowing us to give a more accurate estimate.
Public display of dengue data varied by continent (Figure 8). In
total, 46 of 128 dengue-present countries displayed annual dengue
case numbers. Of these, the highest reporting coverage was
observed in Asia and the Americas where 55% and 57% of
countries respectively reported dengue publically. This figure was
comparably worse in the Pacific (29%) and Africa, Saudi Arabia,
Yemen and the western Indian Ocean islands (Africa+) where just
7% of dengue-present countries publicly report dengue and none
on mainland continental Africa. There were no regional patterns
in the level of dengue case data provided, although the publicising
of epidemiological weeks in some Central and South American
countries tended to provide higher levels of detail. Deaths due to
DHF/DSS/severe dengue were far less commonly reported,
although the data are available for some Central American
countries. Even allowing for variable internet usage and endog-
enous public health systems, we highlight the magnitude of
disparity in countries’ provision of freely available dengue data.
The Americas
Dengue presence is well documented in the Americas with a
continuous set of good- or complete- consensus countries from
southern Brazil to the Mexico-U.S.A. border (Figure 3). However,
a general regional classification was not producible as in some
cases such as Montserrat and Saint Vincent and the Grenadines,
where moderate rather than good consensus was found. With only
22% of dengue-present Caribbean countries displaying dengue
data publically, dengue status in these small island nations that are
characterised by longer inter-epidemic periods proved consider-
ably more heterogeneous. This was mainly due to a lack of
confirmed indigenous cases during recent epidemics.
Other regions of uncertainty reflect dynamic dengue status at
the limits of the disease distribution. Lower consensus estimates in
areas of Florida and Argentina result from reliance on smaller
amounts of evidence from recent epidemics. Although the disease
extent is better described in Florida (both in terms of resolution
and consensus) due to greater data availability, uncertainty is still
present due to the unknown persistence of recent events. A similar
pattern of uncertainty exists in Texas but for different reasons,
being that the occurrence evidence is older and six of seven
counties have no record of occurrence since the late 1980s.
Africa+
A total of 58% of Africa+ countries had a good consensus or
better but Africa still showed the highest levels of uncertainty in
countries with poor consensus. Concentrations of higher consensus
were identified in East and West Africa (Figure 4). Multiple
seroprevalence surveys over several years [31,32,33,34,35] made
the most significant contribution in defining East Africa’s higher-
consensus cluster which ranges from Sudan to Tanzania with only
Uganda, Rwanda and Burundi exhibiting poor or worse evidence
consensus. In addition to this, evidence of outbreaks in coastal
areas of Yemen, Saudi Arabia and some evidence of spill-over into
Egypt added certainty to the definition of the East Africa high-
consensus cluster. Although not as contiguous a tract of countries,
a higher-consensus region also exists in West Africa from Senegal
to Gabon. Inclusion of reported dengue cases in travellers and
soldiers returning from West Africa was available for 13 countries
and proved the most useful information in this region.
Outside of these higher-consensus regions, evidence consensus is
low and a series of countries with moderate or worse consensus
can be identified from Chad to Mozambique with only the
Democratic Republic of Congo exhibiting good evidence consen-
sus. For many of these countries, there are sporadic reports of
dengue occurrence combined with poor disease surveillance and a
general lack of data. Dated seroprevalence surveys in areas where
many other arboviruses are circulating did little to increase
certainty. These factors result in a positive evidence consensus that
is nevertheless highly uncertain in large portions of Africa. Even
Global Dengue Distribution by Evidence Consensus
www.plosntds.org 6 August 2012 | Volume 6 | Issue 8 | e1760Figure 3. Evidence consensus on dengue virus presence and absence in the Americas. Figure 3 shows the areas categorised as complete
evidence consensus on dengue absence in dark green, through to areas with indeterminate evidence consensus on dengue status in yellow, then up
to areas with complete evidence consensus on dengue presence in dark red. Stars indicate one off indigenous transmission events with fewer than
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as in the case of the western Indian Ocean islands, it was often
devalued because there was a lack of clinical differentiation
between dengue and chikungunya despite epidemics coinciding.
The lack of clear clinical distinction between the two diseases [36]
makes the scale of dengue here difficult to identify and as a result,
some countries (such as Reunion) were identified as having low
consensus.
Despite the widespread uncertainty in dengue status in many
African countries, we were able to differentiate multiple levels of
uncertainty. Angola and Mozambique both show lower consensus
due to dated evidence forms, yet they are still distinguishable from
countries with no evidence or just sporadic occurrences such as
Zambia or Congo.
Asia
A wide variety of contemporary evidence allowed us to display a
near continuous distribution of good or complete evidence
consensus countries from Indonesia to as far north as Pakistan
and Zhejiang, China (Figure 5). Within this dengue-present area,
58% of countries publicly displayed dengue data (Figure 8) and
many reported dengue case data with a high spatial resolution.
Minor exceptions to this continuous distribution occur in southern
China and North-East India largely due to a lack of contemporary
evidence. In Gunagxi and Hainan there is little research interest or
case data in recent years despite occurrences in urban centres
further along the Chinese coast [37,38,39]. In North-East India,
lower consensus was observed due to a lack of reported cases in
recent years combined with the arrival of chikungunya in the area
which complicates any potential dengue reporting [40].
Evidence consensus in Asia is lowest in central Asia where
contemporary dengue occurrence records combined with low
surveillance capacity results in an unclear boundary to the disease.
While evidence for dengue presence in the lowland urban centres
of Pakistan is accurate and contemporary, reports from the more
remote north-west provinces are contemporary, but not accurate
[41,42,43]. This makes determining the extent further north into
remote and data-deficient areas of Afghanistan and central Asia
50 cases. The map displays evidence consensus at Admin1 (state) level for Argentina and Uruguay, Admin2 (county) level for the United States of
America and Admin0 (country) level for all other countries.
doi:10.1371/journal.pntd.0001760.g003
Figure 4. Evidence consensus on dengue virus presence and absence in Africa. Figure 4 shows the areas categorised as complete evidence
consensus on dengue absence in dark green, through to areas with indeterminate evidence consensus on dengue status in yellow, then up to areas
with complete evidence consensus on dengue presence in dark red. Stars indicate one off indigenous transmission events with fewer than 50 cases.
The map displays evidence consensus at Admin1 (state) level for Saudi Arabia and Pakistan and Admin0 (country) level for all other countries.
doi:10.1371/journal.pntd.0001760.g004
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www.plosntds.org 8 August 2012 | Volume 6 | Issue 8 | e1760Figure 5. Evidence consensus on dengue virus presence and absence in Asia. Figure 5 shows the areas categorised as complete evidence
consensus on dengue absence in dark green, through to areas with indeterminate evidence consensus on dengue status in yellow, then up to areas
with complete evidence consensus on dengue presence in dark red. Stars indicate one off indigenous transmission events with fewer than 50 cases.
The map displays evidence consensus at Admin1 (state) level for Saudi Arabia, Pakistan, India, China and South Korea and Admin0 (country) level for
all other countries.
doi:10.1371/journal.pntd.0001760.g005
Figure 6. Evidence consensus on dengue virus presence and absence in Europe. Figure 6 shows the areas categorised as complete
evidence consensus on dengue absence in dark green, through to areas with indeterminate evidence consensus on dengue status in yellow. Stars
indicate one off indigenous transmission events with fewer than 50 cases. The map displays evidence consensus at Admin2 (county) level for France
and Croatia and Admin0 (country) level for all other countries.
doi:10.1371/journal.pntd.0001760.g006
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dengue presence in Turkey [44] and Kuwait [45], reducing
evidence consensus for absence in these countries despite not
belonging to any known cluster of dengue-present countries.
Europe
Although no countries in Europe were defined as dengue-
present, sporadic indigenous transmission events have lowered
consensus in some countries (Figure 6). Since the invasion and
spread of Ae. albopictus along the Mediterranean coast [46],
indigenous dengue transmission has been detected in Marseilles,
France and Korc ˇula, Croatia (both regions have moderate
consensus on dengue absence) and chikungunya has been found
in Italy (having good consensus on dengue absence) [47,48,49].
These isolated events do not in themselves confer dengue
presence, but increased surveillance will be required in light of
the Ae. albopictus invasion to maintain this status. This, combined
with the lower levels of healthcare expenditure, has led to an
observed greater uncertainty in some eastern European states.
Australia and Pacific Islands
In general, consensus on dengue presence and absence was well
defined across Australia and the Pacific islands, with 85% of
countries showing good or complete evidence consensus (Figure 7).
Where low consensus was observed, it was largely due to a lack of
contemporary evidence despite Pacific-wide dengue epidemics
such as in Niue, Nauru, Tuvalu and Papua New Guinea. The
duration between epidemics is typically longer in the Pacific and
consensus is subject to continual change; for example, in the
Marshall islands evidence consensus was upgraded from moderate
to complete in the wake of the December 2011 epidemic, which
came two decades after the last reported epidemic [50]. Such
fluctuation is not entirely unexpected from remote, isolated
communities, however. Even though evidence consensus decreases
with time, it still remains positive, allowing for potential re-
occurrence.
Lower evidence consensus was observed for Papua New Guinea
due to a lack of reported case data since the 1980’s, yet multiple
literature sources suggest that dengue is still widespread
[51,52,53]. While dengue occurrence is closely documented in
some counties on the Australian coast, the serologic results from
Charters Towers has contributed to uncertainty over the inland
extent of the disease in Queensland [54]. Only the governments of
Australia, New Caledonia and the Solomon Islands report dengue
case numbers publicly. Considering the long intervals between
epidemics in the Pacific, it is perhaps unsurprising that this is not a
priority.
Discussion
Here we present the distribution of dengue virus transmission as
assessed by evidence-based consensus. By emphasising the need for
accurate, contemporary evidence through a weighted scoring
Figure 7. Evidence consensus on dengue virus presence and absence in Australasia. Figure 7 shows the areas categorised as complete
evidence consensus on dengue absence in dark green, through to areas with indeterminate evidence consensus on dengue status in yellow, then up
to areas with complete evidence consensus on dengue presence in dark red. Stars indicate one off indigenous transmission events with fewer than
50 cases. The map displays evidence consensus at Admin1 (state) level China, Admin2 (county) level for Australia and Admin0 (country) level for all
other countries.
doi:10.1371/journal.pntd.0001760.g007
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uncertain, particularly in Africa and Central Asia, and identify
evidence gaps where surveillance might be better targeted to more
accurately assess dengue status. By including a wide variety of
evidence we were able to cast doubt on dengue status in countries
previously described by health organisations as dengue-absent.
While many studies have focussed on the future threat of
dengue as a result of range expansion or climate change, this is the
first to assess the entirety of knowledge regarding the extent of
current virus transmission. We have found that evidence of dengue
virus transmission is temporally dynamic and that a contemporary
map must emphasise evidence by weighting it appropriately. By
increasing temporal resolution to one inter-epidemic period, we
have extended the approach of Van Kleef et al. [5] who used
evidence from literature searches to produce distribution maps
pre- and post- 1975. Focussing on a higher resolution timescale for
dengue evidence is necessary if we are to infer changes in the
evidence-based distribution of dengue.
The suggestion that dengue is an under-recognised problem in
Africa is not a new one [55,56,57], but here we present a detailed
Table 1. Countries that require a reassessment of dengue status by health organisations.
Country
Evidence
consensus (%)
Health organisations with
dengue-absent status Evidence included
American Samoa Good (76) CDC 2007 outbreak and SE
Aruba Good (67) WHO 2005 outbreak and PCR virus typing
Bahamas Good (67) WHO 2011 outbreak
Benin Moderate (40) WHO, CDC Returning traveller reports, PCR virus typing and SE
Brunei Good (75) WHO 2010 outbreak, PCR virus typing
Cameroon Good (76) WHO Seroprevalence surveys, returning traveller reports and questionnaire responzse
Cayman Islands Good (69) WHO 2010 outbreak and SE
Chad Moderate (40) WHO, CDC Returning traveller reports and SE
Comoros Complete (81) WHO 2010 outbreak, seroprevalence survey and returning traveller reports
Cook Islands Good (60) WHO, CDC 2009 outbreak, PCR virus typing and SE
Djibouti Good (75) WHO 2005 outbreak, returning traveller reports and PCR virus typing
Eritrea Good (63) WHO Returning traveller reports
Fiji Good (69) CDC 2012 outbreak and description of DHF
French Polynesia Good (75) CDC 2009 outbreak, PCR virus typing and description of DHF
Guinea-Bissau Good (60) WHO, CDC Returning traveller reports, questionnaire response and SE
Kiribati Good (71) CDC 2008 outbreak and PCR virus typing
Liberia Poor (29) WHO, CDC Reports of sporadic outbreaks and SE
Maldives Good (71) WHO 2011 outbreak and seroprevalence survey
Marshall Islands Complete (80) CDC 2011 outbreak
Mauritius Good (65) WHO 2009 outbreak, seroprevalence survey and PCR virus typing
Mayotte Good (75) WHO 2005 outbreak, seroprevalence survey and PCR virus typing
Micronesia Good (69) WHO, CDC 2011 outbreak, returning traveller reports, PCR virus typing and description of DHF
Netherlands Antilles Good (75) WHO 2008 outbreak and seroprevalence survey
Nauru Poor (20) CDC PCR virus typing and SE
Niue Good (65) CDC On-going-low level indigenous transmission with reports of sporadic outbreaks
and PCR virus typing
Northern Mariana Islands Moderate (54) CDC 2001 outbreak and seroprevalence survey
Reunion Moderate (43) WHO, CDC 2010 outbreak, PCR virus typing and SE
Samoa Good (68) CDC 2001 outbreak, Returning traveller reports, PCR virus typing
Seychelles Good (63) WHO 2004 outbreak
South Sudan Good (67) WHO PCR virus typing
Togo Poor (30) CDC Returning traveller reports and SE
Tokelau Good (60) CDC 2001 outbreak
Tonga Good (71) CDC 2007 outbreak and returning traveller reports
Turks and Caicos Islands Indeterminate (10) WHO Low level background case data, reported cases in peer-reviewed articles and SE
Tuvalu Poor (30) CDC 1998 outbreak, description of DHF and SE
Wallis and Futuna Good (67) CDC 1998 outbreak, PCR virus typing and SE
Table 1 shows countries for which we identified a consensus better than indeterminate on dengue-presence, but was listed as dengue-absent by the WHO or the CDC.
WHO=World Health Organization, CDC=Centers for Disease Control, SE=supplementary evidence, PCR=polymerase chain reaction, DHF=dengue haemorrhagic
fever.
doi:10.1371/journal.pntd.0001760.t001
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regions. We show that consensus mapping is flexible to regional
differences in evidence availability and as such can produce
meaningful outputs in resource-high and low settings. The
evidence that dengue is widespread in Africa implies that the
continent is underrepresented by occurrence points in the model-
based approaches that have been used to investigate the
distribution of dengue so far [1,10,11]. If we are to estimate the
burden of dengue in Africa with any fidelity, available data and
their underlying assumptions need to be reassessed.
Evidence consensus maps provide a more informative
alternative to existing country-level maps, such as those provided
by the WHO [12] and CDC [58]. As presence or absence exists
on a continuous scale of certainty, evidence consensus approach-
es are more adaptable to incorporating diverse forms of dengue
evidence ignored by these organisations in producing their
estimates. While we show that different evidence weightings in
our scoring system do not significantly alter the result, we were
unable to formalise a statistical validation of these weightings due
to lack of a training dataset. Our results provide the best estimate
thus far of where such data are most needed and comparisons
with higher-consensus countries in similar settings should form
the first step in directing regional surveillance. Development of
methodologies to make approaches such as consensus mapping
more reliable is needed as dengue status will increasingly rely on
harder-to-quantify evidence types, such as internet search engine
terms [59] and multi-language internet text-mining systems
[60,61]. The success of automated disease surveillance systems
such as HealthMap [16,17,62] and Biocaster [60,63] have
already been demonstrated. We believe evidence consensus
provides the best platform for integrating these diverse forms of
information now available for disease occurrence to create an
Table 2. Evidence consensus class changes in Africa as a result of including supplementary evidence and questionnaire responses.
Country
Evidence consensus class excluding
questionnaires and supplementary evidence
Evidence consensus class including
questionnaires and supplementary evidence
Equatorial Guinea Poor (absence) Indeterminate
Mauritania Poor (absence) Indeterminate
Niger Poor (absence) Indeterminate
Central African Republic Indeterminate Poor
Liberia Indeterminate Poor
Malawi Indeterminate Poor
Uganda Indeterminate Poor
Zimbabwe Indeterminate Poor
Angola Poor Moderate
Benin Poor Moderate
Chad Poor Moderate
Guinea-Bissau Poor Good
Cameroon Moderate Good
Co ˆte d’Ivoire Good Complete
Nigeria Good Complete
Sierra Leone Good Complete
All classes refer to consensus on dengue presence unless otherwise stated. Supplementary evidence was available for all countries in this table, while questionnaire
responses were received from Cameroon, Burkina Faso, Malawi, Guinea-Bissau, Gabon and Co ˆte d’Ivoire.
doi:10.1371/journal.pntd.0001760.t002
Figure 8. The worldwide variation in governments that publicly display dengue data. The map shows governments that at a minimum
display dengue case data at a national level yearly via their official Ministry of Health website.
doi:10.1371/journal.pntd.0001760.g008
Global Dengue Distribution by Evidence Consensus
www.plosntds.org 12 August 2012 | Volume 6 | Issue 8 | e1760up-to-date, high-resolution map of dengue evidence, whilst
retaining important assessments of certainty. We also intend to
extend our own data collection and accessibility with a new
website linked to the Global Health Network (http://
globalhealthtrials.tghn.org/) that will allow evidence contribu-
tion from members and will provide a key platform for display of
dengue data and consensus maps. Although the current
approach was used to map the distribution of dengue, minor
modifications to the scoring system would allow it to be utilised
for a variety of diseases for which the quality of presence
evidence is spatially variable.
In this work, our aim was to produce a standardised
methodology that used the largest variety of evidence to assess
country dengue status, whilst still being applicable in diverse
healthcare settings and suitable at multiple spatial scales. We
considered the stark contrast in evidence available in Africa as
compared to the rest of the world. Our results show that the
inclusion of supplementary evidence (used in 44% of African
countries but only 11% of the rest), healthcare expenditure
information (for case data absences) and questionnaires
increased evidence consensus in these countries without
impacting the methodology applied to the rest of the world.
Similarly, we are aware that increasing resolution to Admin1
or Admin2 level may well reduce the evidence available for
calculating evidence consensus in each area compared to
country-level calculations. As a result, we carefully chose which
countries should have increased spatial resolution based on
whether sufficient evidence was available in smaller adminis-
trative units. We also limited the selection of these countries to
those at the limits of the disease’s distribution, as data
deficiencies in these regions more accurately represent the
uncertainty on dengue status given the dynamic nature of
global dengue spread. Here we present the most flexible
methodology available, to date, for overcoming these prob-
lems. We have demonstrated that a systemic approach with
relevant optional categories has allowed us to utilise the
maximum variety of evidence available for assessing dengue
status in the widest variety of situations.
We also openly provide a full list of evidence for each
country by category (Table S1). We intend to continue data
acquisition by including more endogenous, local evidence
through questionnaires and local language search methods,
which we expect will allow us to further customise our
methodology and assess dengue status in places where we are
currently uncertain.
Mapping by evidence consensus is a useful approach to
quantifying contemporary disease evidence and can be further
integrated with geo-spatial modelling to produce worldwide
continuous surfaces of dengue risk [64]. Current mapping
approaches use presence/absence expert opinion maps to sample
pseudo-presence or pseudo-absence points to increase the
number of data points on which to base their prediction
[65,66,67,68]. Pseudo-sampling could be improved by using the
continuous scale of evidence consensus to either affect sample
number or point weight within the geo-spatial model. This will
lead to more robust, higher resolution dengue maps which are
currently in progress [69]. By combining uncertainty assessment
from consensus mapping with high-resolution predictions using
geo-spatial modelling, we will be able to make more accurate
predictions of disease burden with associated confidence intervals
made explicit. This will then provide a series of up-to-date
assessments of global dengue distribution, thus providing key
information to assess dengue spread and the impact of control
measures.
Supporting Information
Figure S1 Geographic locations of occurrence data
globally. Country colouring is based on evidence based
consensus (see main manuscript) with green representing a
complete consensus on dengue absence and red a complete
consensus on dengue presence.
(TIF)
Figure S2 Geographic locations of occurrence data in
Africa+. Country colouring is based on evidence based consensus
(see main manuscript) with green representing a complete
consensus on dengue absence and red a complete consensus on
dengue presence.
(TIF)
Figure S3 Geographic locations of occurrence data in
Asia. Country colouring is based on evidence based consensus
(see main manuscript) with green representing a complete
consensus on dengue absence and red a complete consensus on
dengue presence.
(TIF)
Figure S4 Geographic locations of occurrence data in
the Americas. Country colouring is based on evidence based
consensus (see main manuscript) with green representing a
complete consensus on dengue absence and red a complete
consensus on dengue presence.
(TIF)
Figure S5 Geographic locations of occurrence data in
Australia. Country colouring is based on evidence based
consensus (see main manuscript) with green representing a
complete consensus on dengue absence and red a complete
consensus on dengue presence.
(TIF)
Figure S6 Number of occurrence samples per year
globally (a) and for Africa+ (b), Asia, (c) the Americas
and Australia (d).
(TIF)
Figure S7 Map of evidence types used for each national
and subnational area. Figure S7 shows the different evidence
categories used in assessing evidence consensus for each country
and Admin1/2 area. HO=health organisation status, L=literary
evidence, CD=case data, SE=supplementary evidence, PO=-
professional opinion.
(TIF)
Protocol S1 An outline of the dengue occurrence point
database construction and content. Data sources, searches
and exclusion criteria are outlined and the method of geo-
positioning explained. The regional bias of available occurrence
points is also given in the accompanying figures. Table S1 shows
the collection of evidence used to assess evidence consensus for
each country and Admin1 and Admin2 areas. Details of the
scoring system can be found in the Methods section of the main
manuscript. Scores for each category are highlighted in red.
Evidence consensus is calculated as the percentage of the
maximum possible score (see Fig. 2 in the main manuscript).
HE=healthcare expenditure, DENV=dengue virus, DHF=den-
gue haemorrhagic fever, DSS=dengue shock syndrome,
PCR=polymerase chain reaction, DF=dengue fever.
(DOC)
Table S1 The collection of evidence used to assess
evidence consensus for each country and Admin1 and
Admin2 areas. Details of the scoring system can be found in the
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www.plosntds.org 13 August 2012 | Volume 6 | Issue 8 | e1760Methods section of the main manuscript. Scores for each category
are highlighted in red. Evidence consensus is calculated as the
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